Detail akcie Clene Rg online

Business Summary: Clene Inc. is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis, Parkinson's disease and multiple sclerosis. It specializes in the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its CNM-Au8 is an investigational first-in-class therapy that improves central nervous system cells' survival and function via a mechanism that targets mitochondrial function and the nicotinamide adenine dinucleotide pathway while reducing oxidative stress. Its CNM-ZnAg is a broad-spectrum antiviral, antibacterial agent comprised of zinc (Zn2+) and silver (Ag+) ions under development to treat infectious disease and to provide immune support for symptom resolution. Its CNM-AgZn17 is a gel polymer suspension of Zn2+ and Ag+ under development for treatment of infectious diseases and to support wound healing.
Financial Summary: BRIEF: For the three months ended 31 March 2024, Clene Inc. revenues decreased 32% to $73K. Net loss decreased 6% to $11.1M. Revenues reflect Product revenue decrease of 31% to $44K, Royalty revenue decrease of 33% to $29K. Basic Earnings per Share excluding Extraordinary Items increased from -$3.10 to -$1.73.